Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.
Department of Psychiatry, McLean Hospital, Belmont, MA, USA.
Psychol Med. 2023 Aug;53(11):5001-5011. doi: 10.1017/S0033291722001982. Epub 2022 Jul 15.
Only a limited number of patients with major depressive disorder (MDD) respond to a first course of antidepressant medication (ADM). We investigated the feasibility of creating a baseline model to determine which of these would be among patients beginning ADM treatment in the US Veterans Health Administration (VHA).
A 2018-2020 national sample of = 660 VHA patients receiving ADM treatment for MDD completed an extensive baseline self-report assessment near the beginning of treatment and a 3-month self-report follow-up assessment. Using baseline self-report data along with administrative and geospatial data, an ensemble machine learning method was used to develop a model for 3-month treatment response defined by the Quick Inventory of Depression Symptomatology Self-Report and a modified Sheehan Disability Scale. The model was developed in a 70% training sample and tested in the remaining 30% test sample.
In total, 35.7% of patients responded to treatment. The prediction model had an area under the ROC curve (s.e.) of 0.66 (0.04) in the test sample. A strong gradient in probability (s.e.) of treatment response was found across three subsamples of the test sample using training sample thresholds for high [45.6% (5.5)], intermediate [34.5% (7.6)], and low [11.1% (4.9)] probabilities of response. Baseline symptom severity, comorbidity, treatment characteristics (expectations, history, and aspects of current treatment), and protective/resilience factors were the most important predictors.
Although these results are promising, parallel models to predict response to alternative treatments based on data collected before initiating treatment would be needed for such models to help guide treatment selection.
只有少数患有重度抑郁症(MDD)的患者对首次抗抑郁药物(ADM)治疗有反应。我们调查了创建基线模型的可行性,以确定在美国退伍军人健康管理局(VHA)开始 ADM 治疗的患者中哪些患者属于这一人群。
2018 年至 2020 年,一项全国性样本调查了 660 名接受 ADM 治疗 MDD 的 VHA 患者,他们在治疗开始时完成了一项广泛的基线自我报告评估和 3 个月的自我报告随访评估。使用基线自我报告数据以及行政和地理空间数据,采用集成机器学习方法为 3 个月的治疗反应建立了一个模型,该模型由抑郁症状快速自评量表和改良的 Sheehan 残疾量表定义。该模型在 70%的训练样本中进行开发,并在其余 30%的测试样本中进行测试。
总共有 35.7%的患者对治疗有反应。预测模型在测试样本中的 AUC(s.e.)为 0.66(0.04)。在使用训练样本阈值对高[45.6%(5.5)]、中[34.5%(7.6)]和低[11.1%(4.9)]反应概率的测试样本的三个亚样本中,发现治疗反应的概率(s.e.)有很强的梯度。基线症状严重程度、合并症、治疗特征(期望、历史和当前治疗的各个方面)和保护/恢复力因素是最重要的预测因素。
尽管这些结果很有希望,但需要基于治疗前收集的数据来建立预测其他治疗方法反应的平行模型,以便为治疗选择提供帮助。